Table 1 Population demographic and clinical characteristics for male sub-cohorts
|  |  | LUTS (including OAB) N = 12,383 | BPO only N = 36,307 |
|---|---|---|---|
Age at index date | n | 12,383 | 36,307 |
| Â | Mean (SD) | 65.54 (15.73) | 67.98 (12.47) |
|  | 18–24 | 192 (1.6%) | 119 (0.3%) |
|  | 25–34 | 434 (3.5%) | 356 (1.0%) |
|  | 35–44 | 736 (5.9%) | 997 (2.7%) |
|  | 45–54 | 1438 (11.6%) | 3586 (9.9%) |
|  | 55–64 | 2188 (17.7%) | 7746 (21.3%) |
|  | 65–74 | 3379 (27.3%) | 11,905 (32.8%) |
|  | ≥ 75 | 4016 (32.4%) | 11,598 (31.9%) |
Index of multiple deprivation at index prescription (GP surgery level) | n | 5112 | 16,534 |
|  | 1 = least deprived | 633 (12.4%) | 2770 (16.8%) |
| Â | 2 | 1124 (22.0%) | 3654 (22.1%) |
| Â | 3 | 968 (18.9%) | 3175 (19.2%) |
| Â | 4 | 963 (18.8%) | 2926 (17.7%) |
|  | 5 = most deprived | 1424 (27.9%) | 4009 (24.2%) |
New comorbidities | n | 12,383 | 36,307 |
Count of newly diagnosed chronic diseases from the QOF within the 12-month pre-index period | Mean (SD) | 0.21 (0.50) | 0.22 (0.51) |
| Â | 0 | 10,228 (82.6%) | 29,480 (81.2%) |
| Â | 1 | 1790 (14.5%) | 5700 (15.7%) |
| Â | 2 | 313 (2.5%) | 978 (2.7%) |
| Â | 3+ | 52 (0.4%) | 149 (0.4%) |
Polypharmacy | n | 12,383 | 36,307 |
Number of distinct BNF headers within the 12-month pre-index period | Mean (SD) | 9.81 (7.27) | 8.52 (6.45) |
| Â | 0 | 576 (4.7%) | 1757 (4.8%) |
| Â | [1; 3] | 1931 (15.6%) | 6668 (18.4%) |
| Â | [4; 7] | 2936 (23.7%) | 10,342 (28.5%) |
| Â | [8; 19] | 5707 (46.1%) | 15,220 (41.9%) |
| Â | 20+ | 1233 (10.0%) | 2320 (6.4%) |
Antimuscarinic treatment experience within the 12-month pre-index period | n | 12,383 | 36,307 |
| Â | Yes | 908 (7.3%) | 397 (1.1%) |
| Â | No | 11,475 (92.7%) | 35,910 (98.9%) |